Sign In
Buy IMNM
$22.76
-0.320 (-1.39%)
At Close: Jul 31, 2026
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates
06:51pm, Monday, 12'th May 2025
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.34 per share a year ago.
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade
11:02am, Thursday, 08'th May 2025
The consensus price target hints at a 249.9% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 02'nd May 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome: Transformed Pipeline Offers Multiple Catalysts
06:06am, Thursday, 17'th Apr 2025
Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The comp
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
08:00am, Friday, 04'th Apr 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 03'rd Apr 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates
06:35pm, Wednesday, 19'th Mar 2025
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.54 per share a year ago.
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
04:05pm, Wednesday, 19'th Mar 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
07:41am, Monday, 10'th Mar 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 06'th Mar 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 06'th Feb 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
04:01pm, Friday, 31'st Jan 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announc
Immunome Can Take The Fight To Competitors With Varegacestat
10:27am, Thursday, 30'th Jan 2025
Immunome Can Take The Fight To Competitors With Varegacestat
Immunome Announces Pricing of Upsized Public Offering of Common Stock
11:11pm, Wednesday, 29'th Jan 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announc
Immunome Announces Proposed Public Offering of Common Stock
04:27pm, Wednesday, 29'th Jan 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announc
